Detalhe da pesquisa
1.
Bioactivation and reactivity research advances - 2022 year in review.
Drug Metab Rev
; 55(4): 267-300, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608698
2.
Biotransformation research advances - 2022 year in review.
Drug Metab Rev
; 55(4): 301-342, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37737116
3.
Biotransformation novel advances - 2021 year in review.
Drug Metab Rev
; 54(3): 207-245, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35815654
4.
Bioactivation and reactivity research advances - 2021 year in review.
Drug Metab Rev
; 54(3): 246-281, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876116
5.
Future of Biotransformation Science in the Pharmaceutical Industry.
Drug Metab Dispos
; 50(3): 258-267, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921097
6.
Novel advances in biotransformation and bioactivation research - 2020 year in review.
Drug Metab Rev
; 53(3): 384-433, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33910427
7.
Efavirenz and Efavirenz-like Compounds Activate Human, Murine, and Macaque Hepatic IRE1α-XBP1.
Mol Pharmacol
; 95(2): 183-195, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442673
8.
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.
AIDS
; 36(1): 75-82, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34586085
9.
Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
J Med Chem
; 63(12): 6561-6574, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32065749
10.
Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans.
ACS Pharmacol Transl Sci
; 3(4): 655-665, 2020 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32832868
11.
Probing Ligand Structure-Activity Relationships in Pregnaneâ X Receptor (PXR): Efavirenz and 8-Hydroxyefavirenz Exhibit Divergence in Activation.
ChemMedChem
; 13(7): 736-747, 2018 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29430850